The present study indicates that treatment of baicalein with memantine at doses of 20 + 10 mg/kg significantly reduced the AChE activity in the hippocampus and cortex when compared with the disease control group, which supports its use in the management of AD. Here, ACHE is linked to Alzheimer disease.